Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.58 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.58 |
| ▸ | BRS3 | P32247 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.58 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.58 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.58 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.58 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.58 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.58 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.58 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.58 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.58 |
| ▸ | WDR5 | P61964 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole SCHEMBL3699669 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL1293130 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL1293092 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2513318 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL589808 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2516731 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL6758624 | 0.99 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL5803198 | 0.98 | BRS3 (0.60) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL140006 | 0.98 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL1192 | 0.98 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362259-B2 | Process for the preparation of esomeprazole magnesium in a stable form | LEK PHARMACEUTICALS, D.D. (SI) | 2013-01-29 | — | — | US | disclosed |
| EP-2114918-B1 | PROCESS FOR SOLVENT REMOVAL FROM OMEPRAZOLE SALTS | LEK PHARMACEUTICALS (SI) | 2012-10-03 | — | — | EP | disclosed |
| US-8247567-B2 | Process for solvent removal from omeprazole salts | LEK PHARMACEUTICALS, D.D. (SI) | 2012-08-21 | — | — | US | disclosed |
| EP-1230237-B2 | MAGNESIUM OMEPRAZOLE | SHERMAN BERNARD CHARLES (CA) | 2011-07-20 | — | — | EP | disclosed |
| EP-2328887-A1 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM IN A STABLE FORM | LEK Pharmaceuticals d.d. (SI) | 2011-06-08 | — | — | EP | disclosed |
| US-20100076025-A1 | PROCESS FOR SOLVENT REMOVAL FROM OMEPRAZOLE SALTS | LEK PHARMACEUTICALS D.D. (SI) | 2010-03-25 | — | — | US | disclosed |
| WO-2010010056-A1 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM IN A STABLE FORM | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-28 | — | — | WO | disclosed |
| EP-2147918-A1 | Process for the preparation of S-omeprazole magnesium in a stable form | LEK Pharmaceuticals D.D. (SI) | 2010-01-27 | — | — | EP | disclosed |
| US-20100016370-A1 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM IN A STABLE FORM | LEK PHARMACEUTICALS D.D. (SI) | 2010-01-21 | — | — | US | disclosed |
| EP-2114918-A1 | PROCESS FOR SOLVENT REMOVAL FROM OMEPRAZOLE SALTS | LEK Pharmaceuticals D.D. (SI) | 2009-11-11 | — | — | EP | disclosed |
| EP-1947099-A1 | Process for solvent removal from omeprazole salts | LEK Pharmaceuticals D.D. (SI) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007041790-A1 | SALTS OF PROTON PUMP INHIBITORS AND PROCESS FOR PREPARING SAME | JON PTY LIMITED (AU) | 2007-04-19 | — | — | WO | disclosed |
| EP-1375497-B1 | Magnesium salt of s-omeprazole | SHERMAN BERNARD CHARLES (CA) | 2006-09-20 | — | — | EP | disclosed |
| US-6894066-B2 | Magnesium salt of S-omeprazole | Sherman, Bernard Charles (CA) | 2005-05-17 | — | — | US | disclosed |
| EP-1230237-B1 | MAGNESIUM OMEPRAZOLE | SHERMAN BERNARD CHARLES (CA) | 2004-04-28 | — | — | EP | disclosed |
| US-6713495-B1 | FORMING ORGANIC SOLVENT FREE FORM; FLASH EVAPORATING | Sherman, Bernard Charles (CA) | 2004-03-30 | — | — | US | disclosed |
| EP-1375497-A1 | Magnesium salt of s-omeprazole | Sherman, Bernard Charles (CA) | 2004-01-02 | — | — | EP | disclosed |
| US-20030232861-A1 | Magnesium salt of S-omeprazole | SHERMAN BERNARD CHARLES (CA) | 2003-12-18 | — | — | US | disclosed |
| EP-1230237-A1 | MAGNESIUM OMEPRAZOLE | SHERMAN, Bernard Charles (CA) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001036409-A1 | MAGNESIUM OMEPRAZOLE | SHERMAN BERNARD CHARLES (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016370-A1 | PROCESS FOR THE PREPARATION OF ESOMEPRAZOLE MAGNESIUM IN A STABLE FORM | RPS27A, ATP6AP1, RPS26 | ATP4A 423/4885ATP4B 411/4885BRS3 2623/4885 |
| US-20100076025-A1 | PROCESS FOR SOLVENT REMOVAL FROM OMEPRAZOLE SALTS | TPMT, ABCB11, MLN | ATP4A 299/4885ATP4B 471/4885BRS3 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.